Clinical News

Baricitinib Plus Remdesivir Improves Recovery Time for Hospitalized COVID-19

September 15, 2020

Early data from a phase 3 trial showed that baricitinib combined with remdesivir improved recovery in patients hospitalized with COVID-19 compared with remdesivir alone.

FDA Alert: Efficacy Concerns with Atezolizumab Plus Paclitaxel for Breast Cancer

September 11, 2020

The FDA issued a safety alert about efficacy and potential safety concerns with a combination therapy being studied for the treatment of breast cancer.

FDA OKs Azacitidine Tablets for Acute Myeloid Leukemia

September 03, 2020

Oral azacitidine (Onureg; Celgene) is approved for patients in first remission with acute myeloid leukeimia.

ACIP Updates Flu Vaccine Recommendations for 2020-2021 Season

August 25, 2020

Primary updates to the guidance includes the composition of the 2020-2021 flu vaccines and the recent licensures of 2 new influenza vaccines.

FDA OKs Risdiplam for Treatment of Spinal Muscular Atrophy

August 07, 2020

Risdiplam (Evrysdi; Genentech) is the only SMA therapy that can be administered at home.

FDA OKs New Indication for Esketamine Nasal Spray

August 05, 2020

Esketamine (Spravato; Janssen) CIII nasal spray is the first FDA-approved antidepressant medication that improves depressive symptoms with the first dose in adults with major depressive disorder.

International Panel Issues Weak Recommendation for Remdesivir in Severe COVID-19

August 03, 2020

A panel has given a “weak recommendation” for the use of remdesivir in patients with severe coronavirus disease 2019.

Empagliflozin Reduces Heart Failure Hospitalization, Death Risk in Phase 3 Trial

July 31, 2020

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Moderna’s COVID-19 Vaccine Candidate Shows Safety, Immune Response Results in Phase 1 Study

July 15, 2020

Moderna announced interim analysis results of its investigational COVID-19 vaccine candidate, mRNA-1273, from an ongoing phase 1 study.

FDA Approves Fostemsavir for Heavily Pretreated Patients With HIV

July 03, 2020

Fostemsavir (Rukobia, ViiV Healthcare) is indicated for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.

Reevaluating the Use of Docusate in the Management of Constipation

July 01, 2020

Pharmacists can and must play an active role in guiding patients on the selection of laxatives which are supported by sound evidence.

FDA Approves New Combo Breast Cancer Treatment for Subcutaneous Injection

July 01, 2020

The fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase (Phesgo; Genentech) can be administered subcutaneously for patients with HER2-positive breast cancer.

Part 2: A Conversation on Remdesivir Trial Updates

June 29, 2020

Julie Ann Justo, infectious diseases clinical pharmacist and associate professor at the University of South Carolina College of Pharmacy, discusses the latest data from Gilead's trials for Remdesivir, a potential COVID-19 treatment.

Gilead Sets Price of Remdesivir for COVID-19 Treatment

June 29, 2020

In an open letter, Gilead Chairman and CEO Daniel O’Day announced the price of remdesivir treatment for COVID-19.

FDA OKs New Treatment for Seizures Associated with Dravet Syndrome

June 26, 2020

Officials with the FDA approved fenfluramine (Fintepla, Zogenix) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.

Barhemsys (Amisulpride) for Postoperative Nausea and Vomiting

June 22, 2020

On February 27, 2020, the FDA approved an intravenous solution of amisulpride (Barhemsys; Acacia Pharma) to treat and prevent postoperative nausea and vomiting.

Coronavirus News Roundup: FDA Revokes EUA, NY Law to Ensure Pharmacist-Provided COVID-19 Vaccines

June 19, 2020

Here's a roundup of this week's coronavirus-related news.

Gilead Announces Plans for Pediatric COVID-19 Trial of Remdesivir

June 18, 2020

The phase 2/3 trials will evaluate remdesivir (Gilead) in pediatric patients, from newborns to adolescents, who have contracted severe COVID-19 symptoms.

Studies Reveal Positive Results for Infliximab Biosimilar

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

FDA Releases Drug Interaction Warning for Remdesivir and Hydroxychloroquine

June 15, 2020

The FDA updated its fact sheet on the co-administration of remdesivir with chloroquine phosphate or hydroxychloroquine.